198 related articles for article (PubMed ID: 15285747)
1. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience.
Saito M; Watanabe T; Tabuchi F; Otsubo K; Satoh K; Miyagawa I
Int J Urol; 2004 Aug; 11(8):592-6. PubMed ID: 15285747
[TBL] [Abstract][Full Text] [Related]
2. Treatment of overactive bladder with modified intravesical oxybutynin chloride.
Saito M; Tabuchi F; Otsubo K; Miyagawa I
Neurourol Urodyn; 2000; 19(6):683-8. PubMed ID: 11071699
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
4. The use of intravesical oxybutynin chloride in children with neurogenic bladder.
Greenfield SP; Fera M
J Urol; 1991 Aug; 146(2 ( Pt 2)):532-4. PubMed ID: 1861294
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
[TBL] [Abstract][Full Text] [Related]
6. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
[TBL] [Abstract][Full Text] [Related]
7. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E
Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
[TBL] [Abstract][Full Text] [Related]
8. Treatment with modified intravesical oxybutynin chloride for neurogenic bladder in children.
Hayashi A; Saito M; Okada S; Hanada T; Watanabe T; Satoh K; Kanzaki S
J Pediatr Urol; 2007 Dec; 3(6):438-42. PubMed ID: 18947791
[TBL] [Abstract][Full Text] [Related]
9. Intravesical oxybutynin chloride: experience with 42 patients.
Weese DL; Roskamp DA; Leach GE; Zimmern PE
Urology; 1993 Jun; 41(6):527-30. PubMed ID: 8516987
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
11. Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis.
Shen SH; Jia X; Peng L; Zeng X; Shen H; Luo DY
Int Urol Nephrol; 2022 Apr; 54(4):737-747. PubMed ID: 35226282
[TBL] [Abstract][Full Text] [Related]
12. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients.
Haferkamp A; Staehler G; Gerner HJ; Dörsam J
Spinal Cord; 2000 Apr; 38(4):250-4. PubMed ID: 10822396
[TBL] [Abstract][Full Text] [Related]
13. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder.
Kaplinsky R; Greenfield S; Wan J; Fera M
J Urol; 1996 Aug; 156(2 Pt 2):753-6. PubMed ID: 8683776
[TBL] [Abstract][Full Text] [Related]
14. Can Oral Fesoterodine Be an Alternative for Intravesical Oxybutynin Instillations in Children with Neuropathic Bladder Dysfunction?
van den Heijkant M; De Coster K; Jansen K; Bogaert G
Urol Int; 2019; 103(2):202-210. PubMed ID: 31117096
[TBL] [Abstract][Full Text] [Related]
15. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.
Pannek J; Sommerfeld HJ; Bötel U; Senge T
Urology; 2000 Mar; 55(3):358-62. PubMed ID: 10699610
[TBL] [Abstract][Full Text] [Related]
16. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Efficacy, Safety, and Tolerability of Modified Intravesical Oxybutynin Chloride for Neurogenic Bladder in Children.
Honda M; Kimura Y; Tsounapi P; Hikita K; Saito M; Takenaka A
J Clin Med Res; 2019 Apr; 11(4):256-260. PubMed ID: 30937115
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial.
Schröder A; Albrecht U; Schnitker J; Reitz A; Stein R
Neurourol Urodyn; 2016 Jun; 35(5):582-8. PubMed ID: 25754454
[TBL] [Abstract][Full Text] [Related]
19. [Topical administration of oxybutynin hydrochloride in women with urge incontinence. Results of a prospective randomized double-blind study].
Enzelsberger H; Kurz C; Helmer H; Mittermayer F
Geburtshilfe Frauenheilkd; 1995 May; 55(5):240-3. PubMed ID: 7607378
[TBL] [Abstract][Full Text] [Related]
20. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida.
Ferrara P; D'Aleo CM; Tarquini E; Salvatore S; Salvaggio E
BJU Int; 2001 May; 87(7):674-8. PubMed ID: 11350411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
